Semper Paratus Acquisition Corp. (LGST) Shareholders Approve Tevogen Bio Deal
by Marlena Haddad on 2024-02-01 at 8:58am

Semper Paratus (Nasdaq: LGST) announced this morning that its shareholders approved its combination with Tevogen Bio during a special meeting yesterday January 31.

In connection with the vote, shareholders holding 1,432,457 shares out of a possible 1,502,180 Semper Paratus ordinary shares opted to redeem their shares. While the final amount of the funds to be removed from the trust is still being calculated, the current preliminary calculations are that approximately $15.9 million, or $11.07 per share, will be removed from the trust.

Including prior votes, LGST shareholders have redeemed an aggregate of 99.8% of the SPAC’s trust thus far, leaving it with roughly $800,000 and 69,723 shares remaining.

The parties did not provide a timeline for the closing of the deal, but it is expected to be completed as soon as practicable following the satisfaction of the remaining closing conditions, including approval for listing on The Nasdaq.

Following the closing of the deal, the common stock of the combined company is expected to begin trading on Nasdaq under the symbol “TVGN”.

Semper Paratus inked its $1.2 billion deal with Tevogen Bio in June 2023. Warren, New Jersey-based Tevogen is developing a treatment to boost the immune systems of COVID patients undergoing cancer treatments or that have other comorbidities.

All other proposals presented on the ballot were also approved at the meeting .

Recent Posts
by Nicholas Alan Clayton on 2024-04-17 at 8:13am

At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...

by Nicholas Alan Clayton on 2024-04-16 at 11:33am

Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...

by Nicholas Alan Clayton on 2024-04-16 at 7:58am

At the SPAC of Dawn Ever since Digital World announced its combination with Trump Media (NASDAQ:DJT) back in October 2021, it was clear that SPACworld and the Trump show were set to be intertwined for quite some time. And, although not every headline has a bearing on the wider SPAC world, Trump Media’s post-close rise...

by Nicholas Alan Clayton on 2024-04-15 at 3:47pm

AltC (NYSE:ALCC) has reportedly been taking the pitch deck for its combination with nuclear fission firm Oklo on the road in recent weeks, which has generated the rare result of a SPAC trading significantly above its trust value still well before completing its deal. The SPAC has an estimated $10.59 per share in its trust...

by Nicholas Alan Clayton on 2024-04-15 at 9:35am

Trump Media (NASDAQ:DJT) is down about -15% in the pre-market following the filing of its first S-1 since closing its combination with Digital World, and this includes the issuance of the 21,491,251 shares. Of these, 14,375,000 are to be made available for those exercising warrants while the rest would go out to note holders from...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved